# Gene Therapy in Alzheimer's Disease: Understanding the Role of **Apolipoprotein E in Late Onset Alzheimer's Disease**

# Angela Wei<sup>1,2</sup>, Dominic Tringali<sup>1,2</sup>, Gabriella MacDougall<sup>1,2</sup>, Ashley Kilgore<sup>1,2</sup>, Ornit Chiba-Falek<sup>1,2</sup>

<sup>1</sup>Division of Translational Brain Sciences, Department of Neurology, Duke University Medical Center, Durham, NC 27710, USA; <sup>2</sup>Center for Genomic and Computational Biology, Duke University Medical Center, Durham, NC 27710, USA

## Background

### What is Alzheimer's Disease (AD)?

- A progressive neurodegenerative disease that causes memory loss and cognitive decline
- Late onset Alzheimer's disease (LOAD) is the most common form (affects people ages 65 and older)
- Pathological hallmarks of AD are amyloid plaques and neurofibrillary tangles, associated with amyloid- β protein clustering and tau protein misfolding respectively

### Why Study It?

- AD affects nearly 6 million people in the U.S. and is projected to affect 14 million by 2050
- Causative factors and the mechanism behind its onset and progression remain unknown; no cure currently exists

### The APOE gene can modify your risk of developing Alzheimer's

- <u>APOE ε4 has been identified as the strongest and most</u> reproducible genetic risk factor for LOAD
- APOE has 3 protein variants (isoforms) that vary by a single • nucleotide in two possible positions in their DNA sequence, results in the coding of different amino acids in the protein

Isoform	Frequency	LOAD Risk	
<b>ε4</b> (R112 <i>,</i> R158)	Less common (~14)	Higher (risk)	1 copy= 3- 4 x
			2 copies = 8-12 x
<b>ε3</b> (C112 <i>,</i> R158)	Most common (~79)	Normal (neutral)	
<b>ε2</b> (C112, C158)	Rare (~4)	Lower (resilience)	

# **Our Hypothesis**







Impaired cellular Nuclear dysfunction



BASS CONNECTIONS **Brain & Society**